Author

E. Malfatti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Approach:biophysical modeling· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

A. D'Amico· 1 shared A. Hau· 1 shared A. Oldfors· 1 shared B. Periou· 1 shared C. Hou· 1 shared E. Zanoteli· 1 shared F. J. Authier· 1 shared F. Muntoni· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPhysiology

A. D'Amico

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Human light meromyosin mutations linked to skeletal myopathies disrupt the coiled coil structure and myosin head sequestration

G. Carrington, A. Hau, S. Kosta, H. Dugdale, F. Muntoni, A. D'Amico, P. Van den Bergh, N. Romero, E. Malfatti, J. J. Vilchez, A. Oldfors, S. Pajusalu, K. Ounap, M. Giralt-Pujol, E. Zanoteli, , J. Ochala

This study investigates how mutations in MYH7 and MYH2 genes affect myosin structure and function, finding that they disrupt coiled-coil structure and increase ATP consumption without affecting contractile function.

bioRxiv · May 15, 2023 · PreprintPhysiology

Interferon-gamma mediates skeletal muscle lesions through JAK/STAT pathway activation in inclusion body myositis

C. Hou, B. Periou, M. Gervais, J. Berthier, Y. Baba-Amer, S. Souvannanorath, E. Malfatti, F. Relaix, M. bencze, F. J. Authier

This study shows that IFN-gamma induces skeletal muscle degeneration via JAK/STAT pathway activation in IBM, with ruxolitinib reversing these effects.

bioRxiv · Dec 16, 2021 · PreprintCell Biology